|
1
|
Warnakulasuriya S: Living with oral
cancer: Epidemiology with particular reference to prevalence and
life-style changes that influence survival. Oral Oncol. 46:407–410.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haron N, Zain RB, Nabillah WM, Saleh A,
Kallarakkal TG, Ramanathan A, Sinon SH Mohd, Razak I Abdul and
Cheong SC: Mobile phone imaging in low resource settings for early
detection of oral cancer and concordance with clinical oral
examination. Telemed J E Health. Aug 19–2016.(Epub ahead of print).
PubMed/NCBI
|
|
3
|
Bajpai M, Arora M and Chandolia B:
Bioimpedance for Oral Cancer Detection in Clinical Practice and its
Applicability in Developing Nations. J Coll Physicians Surg Pak.
26:7212016.PubMed/NCBI
|
|
4
|
Ishikawa S, Sugimoto M, Kitabatake K,
Sugano A, Nakamura M, Kaneko M, Ota S, Hiwatari K, Enomoto A, Soga
T, et al: Identification of salivary metabolomic biomarkers for
oral cancer screening. Sci Rep. 6:315202016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Petersen PE: Oral cancer prevention and
control - the approach of the World Health Organization. Oral
Oncol. 45:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bömke C and Tudzynski B: Diversity,
regulation, and evolution of the gibberellin biosynthetic pathway
in fungi compared to plants and bacteria. Phytochemistry.
70:1876–1893. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen J, Sun Z, Zhang Y, Zeng X, Qing C,
Liu J, Li L and Zhang H: Synthesis of gibberellin derivatives with
anti-tumor bioactivities. Bioorg Med Chem Lett. 19:5496–5499. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Zhang H, Chen J, Zhao H, Zeng X,
Zhang H and Qing C: Antitumor and antiangiogenic effects of
GA-13315, a gibberellin derivative. Invest New Drugs. 30:8–16.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Conway DI, Petticrew M, Marlborough H,
Berthiller J, Hashibe M and Macpherson LM: Socioeconomic
inequalities and oral cancer risk: A systematic review and
meta-analysis of case-control studies. Int J Cancer. 122:2811–2819.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Petti S: Lifestyle risk factors for oral
cancer. Oral Oncol. 45:340–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mo J, Kang M, Ye JX, Chen JB, Zhang HB and
Qing C: Gibberellin derivative GA-13315 sensitizes
multidrug-resistant cancer cells by antagonizing ABCB1 while
agonizes ABCC1. Cancer Chemother Pharmacol. 78:51–61. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Zhang H, Chen J, Zhao H, Zeng X,
Zhang H and Qing C: Antitumor and antiangiogenic effects of
GA-13315, a gibberellin derivative. Invest New Drugs. 30:8–16.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mayer RE, Hendrix P, Cron P, Matthies R,
Stone SR, Goris J, Merlevede W, Hofsteenge J and Hemmings BA:
Structure of the 55-kDa regulatory subunit of protein phosphatase
2A: Evidence for a neuronal-specific isoform. Biochemistry.
30:3589–3597. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Holmes SE, O'Hearn EE, McInnis MG,
Gorelick-Feldman DA, Kleiderlein JJ, Callahan C, Kwak NG,
Ingersoll-Ashworth RG, Sherr M, Sumner AJ, et al: Expansion of a
novel CAG trinucleotide repeat in the 5′ region of PPP2R2B is
associated with SCA12. Nat Genet. 23:391–392. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marmorstein LY, McLaughlin PJ, Stanton JB,
Yan L, Crabb JW and Marmorstein AD: Bestrophin interacts physically
and functionally with protein phosphatase 2A. J Biol Chem.
277:30591–30597. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Majchrzak-Celińska A, Słocińska M,
Barciszewska AM, Nowak S and Baer-Dubowska W: Wnt pathway
antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in
gliomas and SFRP1 methylation predicts shorter survival. J Appl
Genet. 57:189–197. 2016. View Article : Google Scholar : PubMed/NCBI
|
